Eric P Hoffman

List of Publications by Year
in descending order

421 papers	32,795 citations	4658 85 h-index	5120 166 g-index
478 all docs	478 docs citations	478 times ranked	26391 citing authors

#	Article	IF	Citations
1	Dystrophin: The protein product of the duchenne muscular dystrophy locus. Cell, 1987, 51, 919-928.	28.9	4,277
2	Characterization of Dystrophin in Muscle-Biopsy Specimens from Patients with Duchenne's or Becker's Muscular Dystrophy. New England Journal of Medicine, 1988, 318, 1363-1368.	27.0	911
3	Multiple-laboratory comparison of microarray platforms. Nature Methods, 2005, 2, 345-350.	19.0	814
4	Glucose Restriction Inhibits Skeletal Myoblast Differentiation by Activating SIRT1 through AMPK-Mediated Regulation of Nampt. Developmental Cell, 2008, 14, 661-673.	7.0	701
5	Duchenne muscular dystrophy: Deficiency of dystrophin at the muscle cell surface. Cell, 1988, 54, 447-452.	28.9	592
6	Sir2 Regulates Skeletal Muscle Differentiation as a Potential Sensor of the Redox State. Molecular Cell, 2003, 12, 51-62.	9.7	542
7	Future Research Directions in Acute Lung Injury. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1027-1035.	5.6	489
8	Immunoelectron microscopic localization of dystrophin in myofibres. Nature, 1988, 333, 863-866.	27.8	450
9	Expression Profiling in the Muscular Dystrophies. Journal of Cell Biology, 2000, 151, 1321-1336.	5.2	448
10	Î²â€“sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nature Genetics, 1995, 11, 266-273.	21.4	438
11	The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature, 1988, 334, 154-156.	27.8	385
12	A Met-to-Val mutation in the skeletal muscle Na+ channel Î±-subunit in hyperkalaemic periodic paralysis. Nature, 1991, 354, 387-389.	27.8	356
13	Efficacy of systemic morpholino exonâ€skipping in duchenne dystrophy dogs. Annals of Neurology, 2009, 65, 667-676.	5.3	356
14	Mutations in the integrin Î±7 gene cause congenital myopathy. Nature Genetics, 1998, 19, 94-97.	21.4	355
15	Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metabolism, 2005, 2, 251-261.	16.2	326
16	Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. Neuron, 1989, 2, 1019-1029.	8.1	320
17	Subcellular fractionation of dystrophin to the triads of skeletal muscle. Nature, 1987, 330, 754-758.	27.8	318
18	Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction. Arthritis and Rheumatism, 2005, 52, 1824-1835.	6.7	308

#	Article	IF	Citations
19	Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet, The, 2018, 391, 451-461.	13.7	306
20	Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rbâ€“MyoD pathways in muscle regeneration. Brain, 2006, 129, 996-1013.	7.6	288
21	Somatic reversion/suppression of the mouse mdx phenotype in vivo. Journal of the Neurological Sciences, 1990, 99, 9-25.	0.6	278
22	Genomics, Intellectual Disability, and Autism. New England Journal of Medicine, 2012, 366, 733-743.	27.0	276
23	ACTN3 genotype is associated with increases in muscle strength in response to resistance training in women. Journal of Applied Physiology, 2005, 99, 154-163.	2.5	262
24	Gene profiling in spinal cord injury shows role of cell cycle in neuronal death. Annals of Neurology, 2003, 53, 454-468.	5.3	261
25	Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-Î². Journal of Clinical Investigation, 2009, 119, 1583-1594.	8.2	251
26	Variability in muscle size and strength gain after unilateral resistance training. Medicine and Science in Sports and Exercise, 2005, 37, 964-72.	0.4	241
27	Contemporary Cardiac Issues in Duchenne Muscular Dystrophy. Circulation, 2015, 131, 1590-1598.	1.6	240
28	Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Annals of Neurology, 2001, 49, 706-711.	5.3	238
29	Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7153-7158.	7.1	235
30	Periodic paralysis in Quarter Horses: a sodium channel mutation disseminated by selective breeding. Nature Genetics, 1992, 2, 144-147.	21.4	224
31	Mutations in the Sarcoglycan Genes in Patients with Myopathy. New England Journal of Medicine, 1997, 336, 618-625.	27.0	223
32	Microtubules Underlie Dysfunction in Duchenne Muscular Dystrophy. Science Signaling, 2012, 5, ra56.	3.6	222
33	Gene Expression Profiling in DQA1*0501+ Children with Untreated Dermatomyositis: A Novel Model of Pathogenesis. Journal of Immunology, 2002, 168, 4154-4163.	0.8	220
34	Deacetylase Inhibitors Increase Muscle Cell Size by Promoting Myoblast Recruitment and Fusion through Induction of Follistatin. Developmental Cell, 2004, 6, 673-684.	7.0	214
35	Cell and fiber type distribution of dystrophin. Neuron, 1988, 1, 411-420.	8.1	210
36	Immune-mediated pathology in Duchenne muscular dystrophy. Science Translational Medicine, 2015, 7, 299rv4.	12.4	209

#	Article	IF	Citations
37	An analysis of DNA methylation in human adipose tissue reveals differential modification of obesity genes before and after gastric bypass and weight loss. Genome Biology, 2015, 16, 8.	8.8	200
38	Loss of emerin at the nuclear envelope disrupts the Rb1/E2F and MyoD pathways during muscle regeneration. Human Molecular Genetics, 2006, 15, 637-651.	2.9	197
39	Mutations in GDP-Mannose Pyrophosphorylase B Cause Congenital and Limb-Girdle Muscular Dystrophies Associated with Hypoglycosylation of Î±-Dystroglycan. American Journal of Human Genetics, 2013, 93, 29-41.	6.2	197
40	Embryonic myogenesis pathways in muscle regeneration. Developmental Dynamics, 2004, 229, 380-392.	1.8	177
41	ACTN3 and MLCK genotype associations with exertional muscle damage. Journal of Applied Physiology, 2005, 99, 564-569.	2.5	171
42	Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping. JAMA Neurology, 2020, 77, 982.	9.0	169
43	The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle and Nerve, 2013, 48, 55-67.	2.2	164
44	Sources of variability and effect of experimental approach on expression profiling data interpretation. BMC Bioinformatics, 2002, 3, 4.	2.6	162
45	The rumpshaker mutation in spastic paraplegia. Nature Genetics, 1994, 7, 351-352.	21.4	158
46	Medium Chain Acyl-CoA Dehydrogenase Deficiency in Pennsylvania: Neonatal Screening Shows High Incidence and Unexpected Mutation Frequencies. Pediatric Research, 1995, 37, 675-678.	2.3	156
47	A web-accessible complete transcriptome of normal human and DMD muscle. Neuromuscular Disorders, 2002, 12, S125-S141.	0.6	156
48	VBP15, a novel antiâ€inflammatory and membraneâ€stabilizer, improves muscular dystrophy without side effects. EMBO Molecular Medicine, 2013, 5, 1569-1585.	6.9	148
49	Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. Nature Communications, 2017, 8, 80.	12.8	147
50	The cooperative international neuromuscular research group duchenne natural history studyâ€"a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used. Muscle and Nerve, 2013, 48, 32-54.	2.2	145
51	Inflammasome Up-Regulation and Activation in Dysferlin-Deficient Skeletal Muscle. American Journal of Pathology, 2010, 176, 2891-2900.	3.8	144
52	Overexcited or inactive: Ion channels in muscle disease. Cell, 1995, 80, 681-686.	28.9	140
53	Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mammalian Genome, 2012, 23, 85-108.	2.2	140
54	Bodywide skipping of exons 45â€"55 in dystrophic mdx52 mice by systemic antisense delivery. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13763-13768.	7.1	139

#	Article	IF	Citations
55	Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology, 2015, 85, 1048-1055.	1.1	138
56	Preclinical drug trials in the mdx mouse: Assessment of reliable and sensitive outcome measures. Muscle and Nerve, 2009, 39, 591-602.	2.2	137
57	An interactive power analysis tool for microarray hypothesis testing and generation. Bioinformatics, 2006, 22, 808-814.	4.1	133
58	Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy. Journal of Cell Biology, 2014, 207, 139-158.	5.2	130
59	GRB14, GPD1, and GDF8 as potential network collaborators in weight loss-induced improvements in insulin action in human skeletal muscle. Physiological Genomics, 2006, 27, 114-121.	2.3	129
60	Response of rat muscle to acute resistance exercise defined by transcriptional and translational profiling. Journal of Physiology, 2002, 545, 27-41.	2.9	127
61	Dystrophin-deficient cardiomyopathy in mouse: Expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscular Disorders, 2008, 18, 371-381.	0.6	127
62	Differential dependency network analysis to identify condition-specific topological changes in biological networks. Bioinformatics, 2009, 25, 526-532.	4.1	127
63	Changes in Ubiquitin Proteasome Pathway Gene Expression in Skeletal Muscle With Exercise and Statins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2560-2566.	2.4	122
64	Metabolite signatures of exercise training in human skeletal muscle relate to mitochondrial remodelling and cardiometabolic fitness. Diabetologia, 2014, 57, 2282-2295.	6.3	121
65	Dystrophin deficiency causes lethal muscle hypertrophy in cats. Journal of the Neurological Sciences, 1992, 110, 149-159.	0.6	120
66	Molecular responses of human muscle to eccentric exercise. Journal of Applied Physiology, 2003, 95, 2485-2494.	2.5	120
67	Congenital muscular dystrophy with primary laminin ?2 (merosin) deficiency presenting as inflammatory myopathy. Annals of Neurology, 1996, 40, 782-791.	5.3	119
68	Interactively optimizing signal-to-noise ratios in expression profiling: project-specific algorithm selection and detection p-value weighting in Affymetrix microarrays. Bioinformatics, 2004, 20, 2534-2544.	4.1	119
69	DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology, 2016, 87, 401-409.	1.1	119
70	Dysferlin Deficiency Enhances Monocyte Phagocytosis. American Journal of Pathology, 2008, 172, 774-785.	3.8	115
71	Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Annals of Neurology, 2004, 55, 195-206.	5.3	114
72	Genetic modifiers of ambulation in the cooperative international Neuromuscular research group Duchenne natural history study. Annals of Neurology, 2015, 77, 684-696.	5.3	111

#	Article	IF	Citations
73	Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Human Molecular Genetics, 2014, 23, 6458-6469.	2.9	106
74	Sexual dimorphism in immune response genes as a function of puberty. BMC Immunology, 2006, 7, 2.	2.2	104
75	A role for mast cells in the progression of Duchenne muscular dystrophy?. Journal of the Neurological Sciences, 1994, 122, 44-56.	0.6	100
76	Multi-omic integrated networks connect DNA methylation and miRNA with skeletal muscle plasticity to chronic exercise in Type 2 diabetic obesity. Physiological Genomics, 2014, 46, 747-765.	2.3	100
77	Balancing muscle hypertrophy and atrophy. Nature Medicine, 2004, 10, 584-585.	30.7	99
78	Slug Is a Novel Downstream Target of MyoD. Journal of Biological Chemistry, 2002, 277, 30091-30101.	3.4	97
79	Proteome Analysis of Skeletal Muscle From Obese and Morbidly Obese Women. Diabetes, 2005, 54, 1283-1288.	0.6	96
80	Expression profiling reveals metabolic and structural components of extraocular muscles. Physiological Genomics, 2002, 9, 71-84.	2.3	94
81	Functional characteristics of dystrophic skeletal muscle: insights from animal models. Journal of Applied Physiology, 2002, 93, 407-417.	2.5	94
82	Congenital Titinopathy: Comprehensive characterization and pathogenic insights. Annals of Neurology, 2018, 83, 1105-1124.	5.3	93
83	Patterns of global gene expression in rat skeletal muscle during unloading and low-intensity ambulatory activity. Physiological Genomics, 2003, 13, 157-167.	2.3	91
84	Skeletal muscle gene expression in response to resistance exercise: sex specific regulation. BMC Genomics, 2010, 11, 659.	2.8	91
85	Laminopathies disrupt epigenomic developmental programs and cell fate. Science Translational Medicine, 2016, 8, 335ra58.	12.4	91
86	Fgfr4 Is Required for Effective Muscle Regeneration in Vivo. Journal of Biological Chemistry, 2006, 281, 429-438.	3.4	90
87	Losartan Decreases Cardiac Muscle Fibrosis and Improves Cardiac Function in Dystrophin-Deficient Mdx Mice. Journal of Cardiovascular Pharmacology and Therapeutics, 2011, 16, 87-95.	2.0	90
88	ACE ID Genotype and the Muscle Strength and Size Response to Unilateral Resistance Training. Medicine and Science in Sports and Exercise, 2006, 38, 1074-1081.	0.4	89
89	Restoring Dystrophin Expression in Duchenne Muscular Dystrophy Muscle. American Journal of Pathology, 2011, 179, 12-22.	3.8	89
90	Is the carboxyl-terminus of dystrophin required for membrane association? A novel, severe case of duchenne muscular dystrophy. Annals of Neurology, 1991, 30, 605-610.	5.3	88

#	Article	IF	Citations
91	Identification of Disease Specific Pathways Using in Vivo SILAC Proteomics in Dystrophin Deficient mdx Mouse. Molecular and Cellular Proteomics, 2013, 12, 1061-1073.	3.8	88
92	The Paradox of Muscle Hypertrophy in Muscular Dystrophy. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, 149-172.	1.3	85
93	Genotype Associations With Increases In Blood Creatine Kinase And Myoglobin Following Intense Eccentric Exercise. Medicine and Science in Sports and Exercise, 2005, 37, S166???S167.	0.4	84
94	Quadriceps myopathy: Forme fruste of Becker muscular dystrophy. Annals of Neurology, 1990, 28, 634-639.	5.3	82
95	Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology, 2012, 79, 159-162.	1.1	81
96	Resistance exercise training influences skeletal muscle immune activation: a microarray analysis. Journal of Applied Physiology, 2012, 112, 443-453.	2.5	79
97	Neuronal plasticity after spinal cord injury: identification of a gene cluster driving neurite outgrowth. FASEB Journal, 2005, 19, 153-154.	0.5	78
98	Metataxonomic and Metagenomic Approaches vs. Culture-Based Techniques for Clinical Pathology. Frontiers in Microbiology, 2016, 7, 484.	3.5	78
99	Discordance of muscular dystrophy in monozygotic female twins: Evidence supporting asymmetric splitting of the inner cell mass in a manifesting carrier of Duchenne dystrophy. American Journal of Medical Genetics Part A, 1991, 40, 354-364.	2.4	76
100	Definition of the unique human extraocular muscle allotype by expression profiling. Physiological Genomics, 2005, 22, 283-291.	2.3	76
101	Deletion of galectinâ€3 exacerbates microglial activation and accelerates disease progression and demise in a <scp>SOD1</scp>^{G93A} mouse model of amyotrophic lateral sclerosis. Brain and Behavior, 2012, 2, 563-575.	2.2	76
102	Probe set algorithms: is there a rational best bet?. BMC Bioinformatics, 2006, 7, 395.	2.6	75
103	Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. Human Mutation, 2008, 29, 728-737.	2.5	75
104	Natural Progression of Childhood Asthma Symptoms and Strong Influence of Sex and Puberty. Annals of the American Thoracic Society, 2014, 11, 939-944.	3.2	75
105	Molecular pathophysiology and targeted therapeutics for muscular dystrophy. Trends in Pharmacological Sciences, 2001, 22, 465-470.	8.7	74
106	A Longitudinal, Integrated, Clinical, Histological and mRNA Profiling Study of Resistance Exercise in Myositis. Molecular Medicine, 2010, 16, 455-464.	4.4	74
107	Forty-eight hours of unloading and 24 h of reloading lead to changes in global gene expression patterns related to ubiquitination and oxidative stress in humans. Journal of Applied Physiology, 2010, 109, 1404-1415.	2.5	74
108	Metabolic remodeling agents show beneficial effects in the dystrophin- deficient mdx mouse model. Skeletal Muscle, 2012, 2, 16.	4.2	74

#	Article	IF	Citations
109	Expression of two temporally distinct microglia-related gene clusters after spinal cord injury. Glia, 2006, 53, 420-433.	4.9	72
110	Homozygous ?-sarcoglycan mutation in two siblings: One asymptomatic and one steroid-responsive mild limb-girdle muscular dystrophy patient. Muscle and Nerve, 1998, 21, 769-775.	2.2	71
111	Association Study of Exon Variants in the NF-Î²B and TGFÎ² Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy. American Journal of Human Genetics, 2016, 99, 1163-1171.	6.2	71
112	Clinical utility of serum biomarkers in Duchenne muscular dystrophy. Clinical Proteomics, 2016, 13, 9.	2.1	70
113	Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle. Journal of Gene Medicine, 1999, 1, 280-289.	2.8	69
114	Endothelial cell activation and neovascularization are prominent in dermatomyositis. Journal of Autoimmune Diseases, 2006, 3, 2.	1.0	69
115	Asthmatic Airway Epithelium Is Intrinsically Inflammatory and Mitotically Dyssynchronous. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 863-869.	2.9	69
116	Extensive and Prolonged Restoration of Dystrophin Expression with Vivo-Morpholino-Mediated Multiple Exon Skipping in Dystrophic Dogs. Nucleic Acid Therapeutics, 2012, 22, 306-315.	3.6	69
117	Single-Molecule Long-Read 16S Sequencing To Characterize the Lung Microbiome from Mechanically Ventilated Patients with Suspected Pneumonia. Journal of Clinical Microbiology, 2014, 52, 3913-3921.	3.9	69
118	Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacological Research, 2018, 136, 140-150.	7.1	69
119	Dystrophin-deficient myofibers are vulnerable to mast cell granule-induced necrosis. Neuromuscular Disorders, 1994, 4, 325-333.	0.6	66
120	Delayed inflammatory mRNA and protein expression after spinal cord injury. Journal of Neuroinflammation, 2011, 8, 130.	7.2	66
121	Primary adhalin deficiency as a cause of muscular dystrophy in patients with normal dystrophin. Annals of Neurology, 1995, 38, 367-372.	5.3	65
122	Prednisoloneâ€induced changes in dystrophic skeletal muscle. FASEB Journal, 2005, 19, 1-23.	0.5	65
123	Relationships between circadian rhythms and modulation of gene expression by glucocorticoids in skeletal muscle. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 295, R1031-R1047.	1.8	64
124	Membrane Sealant Poloxamer P188 Protects Against Isoproterenol Induced Cardiomyopathy in Dystrophin Deficient Mice. BMC Cardiovascular Disorders, 2011, 11, 20.	1.7	64
125	Sphingosine-1-Phosphate Enhances Satellite Cell Activation in Dystrophic Muscles through a S1PR2/STAT3 Signaling Pathway. PLoS ONE, 2012, 7, e37218.	2.5	64
126	miRTarVis: an interactive visual analysis tool for microRNA-mRNA expression profile data. BMC Proceedings, 2015, 9, S2.	1.6	64

#	Article	IF	Citations
127	Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology, 2019, 93, e1312-e1323.	1.1	64
128	Interleukin-15 and interleukin-15RÎ± SNPs and associations with muscle, bone, and predictors of the metabolic syndrome. Cytokine, 2008, 43, 45-53.	3.2	63
129	Functional Polymorphisms Associated with Human Muscle Size and Strength. Medicine and Science in Sports and Exercise, 2004, 36, 1132-1139.	0.4	62
130	Proteomic responses of skeletal and cardiac muscle to exercise. Expert Review of Proteomics, 2011, 8, 361-377.	3.0	62
131	TNF-Î±-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy. Cell Reports, 2015, 12, 1678-1690.	6.4	62
132	Skipping toward Personalized Molecular Medicine. New England Journal of Medicine, 2007, 357, 2719-2722.	27.0	60
133	Integrin Î±7Î²1 in Muscular Dystrophy/Myopathy of Unknown Etiology. American Journal of Pathology, 2002, 160, 2135-2143.	3.8	59
134	A Renaissance for Antisense Oligonucleotide Drugs in Neurology. Archives of Neurology, 2009, 66, 32-8.	4.5	58
135	Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy. Nature Communications, 2017, 8, 14143.	12.8	58
136	Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy. PLoS ONE, 2015, 10, e0141240.	2.5	58
137	Mutations in the Î´-sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy (LGMD2). Neurogenetics, 1997, 1, 49-58.	1.4	57
138	CCL2 and CCR2 polymorphisms are associated with markers of exercise-induced skeletal muscle damage. Journal of Applied Physiology, 2010, 108, 1651-1658.	2.5	57
139	Mathematical modelling of transcriptional heterogeneity identifies novel markers and subpopulations in complex tissues. Scientific Reports, 2016, 6, 18909.	3.3	57
140	Diagnosis and etiology of congenital muscular dystrophy: We are halfway there. Annals of Neurology, 2016, 80, 101-111.	5.3	57
141	Skeletal muscle dictates the fibrinolytic state after exercise training in overweight men with characteristics of metabolic syndrome. Journal of Physiology, 2003, 548, 401-410.	2.9	56
142	Glucocorticoid-Treated Mice Are an Inappropriate Positive Control for Long-Term Preclinical Studies in the mdx Mouse. PLoS ONE, 2012, 7, e34204.	2.5	55
143	Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy. Neuromuscular Disorders, 2001, 11, 350-359.	0.6	54
144	Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens. Physiological Genomics, 2007, 30, 282-299.	2.3	54

#	Article	IF	Citations
145	Progression of volume load and muscular adaptation during resistance exercise. European Journal of Applied Physiology, 2011, 111, 1063-1071.	2.5	54
146	Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids, 2018, 134, 43-52.	1.8	54
147	Recruitment of mast cells to muscle after mild damage. Journal of the Neurological Sciences, 1996, 135, 10-17.	0.6	52
148	Clarifying the boundaries between the inflammatory and dystrophic myopathies: insights from molecular diagnostics and microarrays. Rheumatic Disease Clinics of North America, 2002, 28, 743-757.	1.9	52
149	Exercise training increases electron and substrate shuttling proteins in muscle of overweight men and women with the metabolic syndrome. Journal of Applied Physiology, 2005, 98, 168-179.	2.5	52
150	IGF-II gene region polymorphisms related to exertional muscle damage. Journal of Applied Physiology, 2007, 102, 1815-1823.	2.5	52
151	Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit. Molecular Therapy, 2018, 26, 2231-2242.	8.2	51
152	Microarray Analysis Reveals Novel Features of the Muscle Aging Process in Men and Women. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2013, 68, 1035-1044.	3.6	50
153	VBP15: Preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorganic and Medicinal Chemistry, 2013, 21, 2241-2249.	3.0	50
154	Chapter 8 The Animal Models of Duchenne Muscular Dystrophy: Windows on the Pathophysiological Consequences of Dystrophin Deficiency. Current Topics in Membranes, 1991, , 113-154.	0.9	49
155	Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Science Alliance, 2019, 2, e201800186.	2.8	49
156	Novel Approaches to Corticosteroid Treatment in Duchenne Muscular Dystrophy. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, 821-828.	1.3	48
157	Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies. Discovery Medicine, 2013, 16, 233-9.	0.5	48
158	The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface. Nucleic Acids Research, 2004, 32, 578D-581.	14.5	47
159	Myostatin and Follistatin Polymorphisms Interact with Muscle Phenotypes and Ethnicity. Medicine and Science in Sports and Exercise, 2009, 41, 1063-1071.	0.4	46
160	Limbâ€“Girdle and Congenital Muscular Dystrophies: Current Diagnostics, Management, and Emerging Technologies. Current Neurology and Neuroscience Reports, 2010, 10, 267-276.	4.2	46
161	Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease. Clinical and Translational Gastroenterology, 2016, 7, e192.	2.5	46
162	Gene expression and muscle fiber function in a porcine ICU model. Physiological Genomics, 2009, 39, 141-159.	2.3	45

#	Article	IF	Citations
163	Rhinovirus infection in young children is associated with elevated airway TSLP levels. European Respiratory Journal, 2014, 44, 1075-1078.	6.7	45
164	Regional localization of the murine Duchenne muscular dystrophy gene on the mouse X chromosome. Somatic Cell and Molecular Genetics, 1987, 13, 671-678.	0.7	44
165	VOLTAGE-GATED ION CHANNELOPATHIES: Inherited Disorders Caused by Abnormal Sodium, Chloride, and Calcium Regulation in Skeletal Muscle. Annual Review of Medicine, 1995, 46, 431-441.	12.2	44
166	Phospholipase A2 activity in dystrophinopathies. Neuromuscular Disorders, 1995, 5, 193-199.	0.6	44
167	A dystrophin missense mutation showing persistence of dystrophin and dystrophin-associated proteins yet a severe phenotype. Annals of Neurology, 1998, 44, 971-976.	5.3	44
168	Pharmacologic Management of Duchenne Muscular Dystrophy: Target Identification and Preclinical Trials. ILAR Journal, 2014, 55, 119-149.	1.8	44
169	Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle. Nature Communications, 2017, 8, 941.	12.8	44
170	Autosomal recessive muscular dystrophy and mutations of the sarcoglycan complex. Neuromuscular Disorders, 1996, 6, 475-482.	0.6	43
171	Decreased Asialotransferrin in Cerebrospinal Fluid of Patients with Childhood-Onset Ataxia and Central Nervous System Hypomyelination/Vanishing White Matter Disease. Clinical Chemistry, 2005, 51, 2031-2042.	3.2	43
172	InÂvitro analysis of metabolites from the untreated tissue of Torpedo californica electric organ by mid-infrared laser ablation electrospray ionization mass spectrometry. Metabolomics, 2009, 5, 263-276.	3.0	42
173	Differential gene expression and a functional analysis of PCB-exposed children: Understanding disease and disorder development. Environment International, 2012, 40, 143-154.	10.0	42
174	Analysis of the toxicogenomic effects of exposure to persistent organic pollutants (POPs) in Slovakian girls: Correlations between gene expression and disease risk. Environment International, 2012, 39, 188-199.	10.0	42
175	Muscle maturation: implications for gene therapy. Trends in Molecular Medicine, 1998, 4, 214-220.	2.6	41
176	Efficacy and safety of vamorolone in Duchenne muscular dystrophy:ÂAn 18-month interim analysis of a non-randomized open-label extension study. PLoS Medicine, 2020, 17, e1003222.	8.4	41
177	In utero fetal muscle biopsy for the diagnosis of Duchenne muscular dystrophy. American Journal of Obstetrics and Gynecology, 1991, 165, 728-732.	1.3	40
178	In vivo filtering of in vitro expression data reveals MyoD targets. Comptes Rendus - Biologies, 2003, 326, 1049-1065.	0.2	40
179	PCB congener specific oxidative stress response by microarray analysis using human liver cell line. Environment International, 2010, 36, 907-917.	10.0	40
180	Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. Scientific Reports, 2016, 6, 31727.	3.3	40

#	Article	IF	Citations
181	Antisense Oligo-Mediated Multiple Exon Skipping in a Dog Model of Duchenne Muscular Dystrophy. Methods in Molecular Biology, 2011, 709, 299-312.	0.9	39
182	DDN: a caBIGÂ® analytical tool for differential network analysis. Bioinformatics, 2011, 27, 1036-1038.	4.1	39
183	Intracellular expression profiling by laser capture microdissection: three novel components of the neuromuscular junction. Physiological Genomics, 2005, 21, 70-80.	2.3	38
184	Dysferlin Deficiency Shows Compensatory Induction of Rab27A/Slp2a That May Contribute to Inflammatory Onset. American Journal of Pathology, 2008, 173, 1476-1487.	3.8	38
185	Role of the nerve in determining fetal skeletal muscle phenotype. , 1998, 211, 177-190.		37
186	PPARÎ± L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. BMC Medical Genetics, 2007, 8, 55.	2.1	37
187	Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the mdx Mouse Model of Duchenne Muscular Dystrophy. PLoS ONE, 2010, 5, e11220.	2.5	37
188	Sparing of the Dystrophin-Deficient Cranial Sartorius Muscle Is Associated with Classical and Novel Hypertrophy Pathways in GRMD Dogs. American Journal of Pathology, 2013, 183, 1411-1424.	3.8	37
189	Î±-Sarcoglycan (adhalin) deficiency: complete deficiency patients are 5% of childhood-onset dystrophin-normal muscular dystrophy and most partial deficiency patients do not have gene mutations. Journal of the Neurological Sciences, 1996, 140, 30-39.	0.6	36
190	X-inactivation patterns in female Leber's hereditary optic neuropathy patients do not support a strong X-linked determinant. , 1996, 61, 356-362.		36
191	TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy. European Journal of Human Genetics, 2020, 28, 815-825.	2.8	36
192	Genetic modifiers of respiratory function in Duchenne muscular dystrophy. Annals of Clinical and Translational Neurology, 2020, 7, 786-798.	3.7	36
193	Clinical and Histopathological Features of Abnormalities of the Dystrophinâ€Based Membrane Cytoskeleton. Brain Pathology, 1996, 6, 49-61.	4.1	35
194	Murine Cytomegalovirus Infection Increases Aortic Expression of Proatherosclerotic Genes. Circulation, 2004, 109, 893-897.	1.6	35
195	Time Series Proteome Profiling To Study Endoplasmic Reticulum Stress Response. Journal of Proteome Research, 2008, 7, 2435-2444.	3.7	35
196	A novel mutation expands the genetic and clinical spectrum of MYH7-related myopathies. Neuromuscular Disorders, 2013, 23, 432-436.	0.6	35
197	Alterations in Osteopontin Modify Muscle Size in Females in Both Humans and Mice. Medicine and Science in Sports and Exercise, 2013, 45, 1060-1068.	0.4	35
198	Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy. Scientific Reports, 2019, 9, 12167.	3.3	35

#	Article	IF	Citations
199	Asymptomatic dystrophinopathy. , 1997, 69, 261-267.		34
200	Differences in fat and muscle mass associated with a functional human polymorphism in a postâ€transcriptional BMP2 gene regulatory element. Journal of Cellular Biochemistry, 2009, 107, 1073-1082.	2.6	34
201	CCL2 and CCR2 variants are associated with skeletal muscle strength and change in strength with resistance training. Journal of Applied Physiology, 2010, 109, 1779-1785.	2.5	34
202	Genome-wide identification of significant aberrations in cancer genome. BMC Genomics, 2012, 13, 342.	2.8	34
203	Exon-Skipping in Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2021, 8, S343-S358.	2.6	34
204	Global gene expression and Ingenuity biological functions analysis on PCBs 153 and 138 induced human PBMC in vitro reveals differential mode(s) of action in developing toxicities. Environment International, 2011, 37, 838-857.	10.0	32
205	Exon-Skipping Therapy: A Roadblock, Detour, or Bump in the Road?. Science Translational Medicine, 2014, 6, 230fs14.	12.4	32
206	Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry. Journal of Bioanalysis & Biomedicine, 2012, s7, .	0.1	32
207	Transcriptional deficits in oxidative phosphorylation with statin myopathy. Muscle and Nerve, 2011, 44, 393-401.	2.2	31
208	Novel Col12A1 variant expands the clinical picture of congenital myopathies with extracellular matrix defects. Muscle and Nerve, 2017, 55, 277-281.	2.2	31
209	Genotype/phenotype correlations in Duchenne/Becker dystrophy. , 1993, 3, 12-36.		31
210	Characterization of Dysferlin Deficient SJL/J Mice to Assess Preclinical Drug Efficacy: Fasudil Exacerbates Muscle Disease Phenotype. PLoS ONE, 2010, 5, e12981.	2.5	31
211	The Muscle Strength and Size Response to Upper Arm, Unilateral Resistance Training Among Adults Who Are Overweight and Obese. Journal of Strength and Conditioning Research, 2007, 21, 307.	2.1	31
212	Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy. JAMA Network Open, 2022, 5, e2144178.	5.9	31
213	Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2022, 9, 493-501.	2.6	31
214	A robust in vitro screening assay to identify NF-ÎºB inhibitors for inflammatory muscle diseases. International Immunopharmacology, 2009, 9, 1209-1214.	3.8	30
215	Mechanisms underlying the sparing of masticatory versus limb muscle function in an experimental critical illness model. Physiological Genomics, 2011, 43, 1334-1350.	2.3	30
216	The ACTN3 R577X Polymorphism Is Associated with Cardiometabolic Fitness in Healthy Young Adults. PLoS ONE, 2015, 10, e0130644.	2.5	30

#	Article	IF	Citations
217	Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone. Physiological Genomics, 2018, 50, 735-745.	2.3	30
218	Duchenne-Becker Muscular Dystrophy and the Nondystrophic Myotonias. Archives of Neurology, 1993, 50, 1227.	4.5	29
219	Resistin Polymorphisms Are Associated with Muscle, Bone, and Fat Phenotypes in White Men and Women. Obesity, 2007, 15, 392-402.	3.0	29
220	AKT1 polymorphisms are associated with risk for metabolic syndrome. Human Genetics, 2011, 129, 129-139.	3.8	29
221	A long-read RNA-seq approach to identify novel transcripts of very large genes. Genome Research, 2020, 30, 885-897.	5.5	29
222	Genetic counseling of isolated carriers of Duchenne muscular dystrophy. , 1996, 63, 573-580.		28
223	Moderate-Intensity Aerobic Training Program Improves Insulin Sensitivity and Inflammatory Markers in a Pilot Study of Morbidly Obese Minority Teens. Pediatric Exercise Science, 2013, 25, 12-26.	1.0	28
224	Muscle histology in becker muscular dystrophy. Muscle and Nerve, 1991, 14, 1067-1073.	2.2	27
225	Unique PABP2 mutations in ?Cajuns? suggest multiple founders of oculopharyngeal muscular dystrophy in populations with French ancestry. , 1999, 86, 477-481.		27
226	Non-invasive Optical Imaging of Muscle Pathology in mdx Mice Using Cathepsin Caged Near-Infrared Imaging. Molecular Imaging and Biology, 2011, 13, 462-470.	2.6	27
227	Î”-9,11 Modification of Glucocorticoids Dissociates Nuclear Factor-ÎºB Inhibitory Efficacy from Glucocorticoid Response Element-Associated Side Effects. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 225-232.	2.5	27
228	Impaired autophagy, chaperone expression, and protein synthesis in response to critical illness interventions in porcine skeletal muscle. Physiological Genomics, 2013, 45, 477-486.	2.3	27
229	Neck and Waist Circumference Biomarkers of Cardiovascular Risk in a Cohort of Predominantly African-American College Students: A Preliminary Study. Journal of the Academy of Nutrition and Dietetics, 2014, 114, 107-116.	0.8	27
230	Exome Sequencing Identifies DYNC1H1 Variant Associated With Vertebral Abnormality and Spinal Muscular Atrophy With Lower Extremity Predominance. Pediatric Neurology, 2015, 52, 239-244.	2.1	27
231	The discovery of dystrophin, the protein product of the Duchenne muscular dystrophy gene. FEBS Journal, 2020, 287, 3879-3887.	4.7	27
232	Knowledge-fused differential dependency network models for detecting significant rewiring in biological networks. BMC Systems Biology, 2014, 8, 87.	3.0	26
233	Elusive sources of variability of dystrophin rescue by exon skipping. Skeletal Muscle, 2015, 5, 44.	4.2	26
234	Upregulated IL-1Î² in dysferlin-deficient muscle attenuates regeneration by blunting the response to pro-inflammatory macrophages. Skeletal Muscle, 2015, 5, 24.	4.2	26

#	Article	IF	Citations
235	Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. PLoS ONE, 2016, 11, e0153461.	2.5	26
236	Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24285-24293.	7.1	26
237	Muscle Weakness in Myositis: MicroRNAâ€Mediated Dystrophin Reduction in a Myositis Mouse Model and Human Muscle Biopsies. Arthritis and Rheumatology, 2020, 72, 1170-1183.	5.6	26
238	Non-Invasive MRI and Spectroscopy of mdx Mice Reveal Temporal Changes in Dystrophic Muscle Imaging and in Energy Deficits. PLoS ONE, 2014, 9, e112477.	2.5	26
239	Recent advances in dystrophin research. Current Opinion in Neurobiology, 1991, 1, 420-429.	4.2	25
240	A polymorphism near IGF1 is associated with body composition and muscle function in women from the Health, Aging, and Body Composition Study. European Journal of Applied Physiology, 2010, 110, 315-324.	2.5	25
241	Subcutaneous Fat Alterations Resulting from an Upper-Body Resistance Training Program. Medicine and Science in Sports and Exercise, 2007, 39, 1177-1185.	0.4	24
242	Mathematical Modeling of Corticosteroid Pharmacogenomics in Rat Muscle following Acute and Chronic Methylprednisolone Dosing. Molecular Pharmaceutics, 2008, 5, 328-339.	4.6	24
243	CNTF 1357 G â†' A polymorphism and the muscle strength response to resistance training. Journal of Applied Physiology, 2009, 107, 1235-1240.	2.5	24
244	VBP15, a Glucocorticoid Analogue, Is Effective at Reducing Allergic Lung Inflammation in Mice. PLoS ONE, 2013, 8, e63871.	2.5	24
245	The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse. Toxicology Reports, 2015, 2, 838-849.	3.3	24
246	PCB exposure and potential future cancer incidence in Slovak children: an assessment from molecular finger printing by Ingenuity Pathway Analysis (IPAÂ®) derived from experimental and epidemiological investigations. Environmental Science and Pollution Research, 2018, 25, 16493-16507.	5.3	24
247	Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. Steroids, 2018, 140, 159-166.	1.8	24
248	Duchenne and Becker Muscular Dystrophies: Genetics, Prenatal Diagnosis, and Future Prospects. Clinics in Perinatology, 1990, 17, 845-863.	2.1	23
249	Plasma membrane cytoskeleton of muscle: a fine structural analysis. , 2000, 48, 131-141.		23
250	Knowledge-guided multi-scale independent component analysis for biomarker identification. BMC Bioinformatics, 2008, 9, 416.	2.6	23
251	Glucocorticoid Efficacy in Asthma is Improved Tissue Remodeling Upstream of Anti-Inflammation. Journal of Investigative Medicine, 2010, 58, 19-22.	1.6	23
252	Short Read (Next-Generation) Sequencing. Circulation: Cardiovascular Genetics, 2013, 6, 427-434.	5.1	23

#	Article	IF	Citations
253	Differential Gene Expression Reveals Mitochondrial Dysfunction in an Imprinting Center Deletion Mouse Model of Praderâ€“Willi Syndrome. Clinical and Translational Science, 2013, 6, 347-355.	3.1	23
254	Recessive ACTA1 variant causes congenital muscular dystrophy with rigid spine. European Journal of Human Genetics, 2015, 23, 883-886.	2.8	23
255	Molecular Diagnosis and Modern Management of Duchenne Muscular Dystrophy. Neurologic Clinics, 1994, 12, 699-725.	1.8	22
256	Automated sequence screening of the entire dystrophin cdna in Duchenne dystrophy: Point mutation detection. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 44-50.	1.7	22
257	Proteomics and Systems Biology in Exercise and Sport Sciences Research. Exercise and Sport Sciences Reviews, 2007, 35, 5-11.	3.0	22
258	INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men. BMC Medical Genetics, 2008, 9, 117.	2.1	22
259	Motif-directed network component analysis for regulatory network inference. BMC Bioinformatics, 2008, 9, S21.	2.6	22
260	TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle. Journal of Pathology, 2012, 228, 251-259.	4.5	22
261	Highlights from the Functional Single Nucleotide Polymorphisms Associated with Human Muscle Size and Strength or FAMuSS Study. BioMed Research International, 2013, 2013, 1-11.	1.9	22
262	The effects of MyD88 deficiency on disease phenotype in dysferlin-deficient A/J mice: role of endogenous TLR ligands. Journal of Pathology, 2013, 231, 199-209.	4.5	22
263	Eccentric muscle challenge shows osteopontin polymorphism modulation of muscle damage. Human Molecular Genetics, 2014, 23, 4043-4050.	2.9	22
264	Molecular biology of Duchenne muscular dystrophy. Trends in Neurosciences, 1988, 11, 480-484.	8.6	21
265	VBP15, a Novel Anti-Inflammatory, is Effective at Reducing the Severity of Murine Experimental Autoimmune Encephalomyelitis. Cellular and Molecular Neurobiology, 2015, 35, 377-387.	3.3	21
266	Investigation of gene Expression in C2C12 Myotubes Following simvastatin Application and Mechanical Strain. Journal of Atherosclerosis and Thrombosis, 2009, 16, 21-29.	2.0	20
267	Variants of the Ankyrin Repeat Domain 6 Gene (ANKRD6) and Muscle and Physical Activity Phenotypes Among European-Derived American Adults. Journal of Strength and Conditioning Research, 2012, 26, 1740-1748.	2.1	20
268	SLC30A8 Nonsynonymous Variant Is Associated With Recovery Following Exercise and Skeletal Muscle Size and Strength. Diabetes, 2014, 63, 363-368.	0.6	20
269	Muscular Dystrophy. Archives of Pathology and Laboratory Medicine, 1999, 123, 1050-1052.	2.5	20
270	In utero fetal muscle biopsy for the diagnosis of Duchenne muscular dystrophy in a female fetus â€œsuddenly at riskâ€• American Journal of Medical Genetics Part A, 1993, 46, 309-312.	2.4	19

#	Article	IF	Citations
271	Private ?- and ?-sarcoglycan gene mutations: Evidence of a founder effect in Northern Italy. Human Mutation, 2000, 16, 13-17.	2.5	19
272	The proteome survey of an electricity-generating organ(Torpedo californicaelectric organ). Proteomics, 2007, 7, 617-627.	2.2	19
273	Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin Î²-4 in the Dystrophin Deficient Mouse. PLoS ONE, 2010, 5, e8976.	2.5	19
274	PUGSVM: a caBIGTM analytical tool for multiclass gene selection and predictive classification. Bioinformatics, 2011, 27, 736-738.	4.1	19
275	Characterization of transferrin glycopeptide structures in human cerebrospinal fluid. International Journal of Mass Spectrometry, 2012, 312, 97-106.	1.5	19
276	Transcriptional profiling and biological pathway analysis of human equivalence PCB exposure in vitro: Indicator of disease and disorder development in humans. Environmental Research, 2015, 138, 202-216.	7.5	19
277	OPNâ€a induces muscle inflammation by increasing recruitment and activation of proâ€inflammatory macrophages. Experimental Physiology, 2016, 101, 1285-1300.	2.0	19
278	miRTarVis+: Web-based interactive visual analytics tool for microRNA target predictions. Methods, 2017, 124, 78-88.	3.8	19
279	Serum biomarkers associated with baseline clinical severity in young steroid-naÃ¯ve Duchenne muscular dystrophy boys. Human Molecular Genetics, 2020, 29, 2481-2495.	2.9	19
280	Hyperkalemic periodic paralysis with cardiac dysrhythmia: A novel sodium channel mutation?. Annals of Neurology, 1995, 37, 408-411.	5.3	18
281	Confocal analysis of the dystrophin protein complex in muscular dystrophy. Muscle and Nerve, 2001, 24, 262-272.	2.2	18
282	Somatic mosaicism for Duchenne dystrophy: Evidence for genetic normalization mitigating muscle symptoms. American Journal of Medical Genetics, Part A, 2009, 149A, 1499-1503.	1.2	18
283	Targeted Re-Sequencing Emulsion PCR Panel for Myopathies: Results in 94 Cases. Journal of Neuromuscular Diseases, 2016, 3, 209-225.	2.6	18
284	African-American esophageal squamous cell carcinoma expression profile reveals dysregulation of stress response and detox networks. BMC Cancer, 2017, 17, 426.	2.6	18
285	Human muscle stem cells are refractory to aging. Aging Cell, 2021, 20, e13411.	6.7	18
286	X inactivation and dystrophin studies in a t(X;12) female: Evidence for biochemical normalization in Duchenne muscular dystrophy carriers. American Journal of Medical Genetics Part A, 1992, 43, 1012-1015.	2.4	17
287	MC4R Variant Is Associated With BMI but Not Response to Resistance Training in Young Females. Obesity, 2011, 19, 662-666.	3.0	17
288	Mexiletine for Treatment of Myotonia. JAMA - Journal of the American Medical Association, 2012, 308, 1377.	7.4	17

#	Article	IF	Citations
289	KDDN: an open-source Cytoscape app for constructing differential dependency networks with significant rewiring. Bioinformatics, 2015, 31, 287-289.	4.1	17
290	Pharmacotherapy of Duchenne Muscular Dystrophy. Handbook of Experimental Pharmacology, 2019, 261, 25-37.	1.8	17
291	Functional recovery of glycine receptors in spastic murine model of startle disease. Neurobiology of Disease, 2006, 21, 291-304.	4.4	16
292	CYP1A1 and MT1K are congener specific biomarker genes for liver diseases induced by PCBs. Environmental Toxicology and Pharmacology, 2008, 25, 218-221.	4.0	16
293	Role of sepsis in the development of limb muscle weakness in a porcine intensive care unit model. Physiological Genomics, 2012, 44, 865-877.	2.3	16
294	Morpholinoâ€induced exon skipping stimulates cellâ€mediated and humoral responses to dystrophin in mdx mice. Journal of Pathology, 2019, 248, 339-351.	4.5	16
295	Delineation of a Gene Network Underlying the Pulmonary Response to Oxidative Stress in Asthma. Journal of Investigative Medicine, 2009, 57, 756-764.	1.6	15
296	The 1p13.3 LDL (C)-Associated Locus Shows Large Effect Sizes in Young Populations. Pediatric Research, 2011, 69, 538-543.	2.3	15
297	Effects of corticosteroids in the development of limb muscle weakness in a porcine intensive care unit model. Physiological Genomics, 2013, 45, 312-320.	2.3	15
298	Obesity-Related Genetic Variants and their Associations with Physical Activity. Sports Medicine - Open, 2015, 1, 34.	3.1	15
299	Integrated genomics and proteomics of the Torpedo californica electric organ: concordance with the mammalian neuromuscular junction. Skeletal Muscle, 2011, 1, 20.	4.2	14
300	Molecular Basis of Neuromuscular Disease. Physical Medicine and Rehabilitation Clinics of North America, 1998, 9, 49-81.	1.3	13
301	Collaborative translational research leading to multicenter clinical trials in Duchenne muscular dystrophy: the Cooperative International Neuromuscular Research Group (CINRG). Neuromuscular Disorders, 2002, 12, S147-S154.	0.6	13
302	Association of Age with Muscle Size and Strength Before and After Short-Term Resistance Training in Young Adults. Journal of Strength and Conditioning Research, 2009, 23, 1915-1920.	2.1	13
303	Motif-guided sparse decomposition of gene expression data for regulatory module identification. BMC Bioinformatics, 2011, 12, 82.	2.6	13
304	Developmental Pharmacodynamics and Modeling in Pediatric Drug Development. Journal of Clinical Pharmacology, 2019, 59, S87-S94.	2.0	13
305	Absolute quantification of dystrophin protein in human muscle biopsies using parallel reaction monitoring (PRM). Journal of Mass Spectrometry, 2020, 55, e4437.	1.6	13
306	Elevation of fast but not slow troponin I in the circulation of patients with Becker and Duchenne muscular dystrophy. Muscle and Nerve, 2021, 64, 43-49.	2.2	13

#	Article	IF	Citations
307	Proteolytic fragment or new gene product?. Nature, 1988, 336, 210-210.	27.8	12
308	Allometric Scaling of Biceps Strength before and after Resistance Training in Men. Medicine and Science in Sports and Exercise, 2007, 39, 1013-1019.	0.4	12
309	caBIGâ„¢ VISDA: Modeling, visualization, and discovery for cluster analysis of genomic data. BMC Bioinformatics, 2008, 9, 383.	2.6	12
310	GeneShelf: A Web-based Visual Interface for Large Gene Expression Time-Series Data Repositories. IEEE Transactions on Visualization and Computer Graphics, 2009, 15, 905-912.	4.4	12
311	Mitotic Asynchrony Induces Transforming Growth Factor-Î²1 Secretion from Airway Epithelium. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 363-369.	2.9	12
312	The Relationship between Coronary Artery Disease Risk Factors and Carotid Intima-Media Thickness in Children. Journal of Pediatrics, 2017, 190, 38-42.	1.8	12
313	Osteopontin is linked with AKT, FoxO1, and myostatin in skeletal muscle cells. Muscle and Nerve, 2017, 56, 1119-1127.	2.2	12
314	Functional characterization of a haplotype in the AKT1 gene associated with glucose homeostasis and metabolic syndrome. Human Genetics, 2010, 128, 635-645.	3.8	11
315	Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients. Rheumatology, 2016, 55, 1673-1680.	1.9	11
316	Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy. Journal of Clinical Pharmacology, 2019, 59, 979-988.	2.0	11
317	MicroRNA Profiling in Adipose Before and After Weight Loss Highlights the Role of miRâ€223â€3p and the NLRP3 Inflammasome. Obesity, 2020, 28, 570-580.	3.0	11
318	Counting muscular dystrophies in the post-molecular census. Journal of the Neurological Sciences, 1999, 164, 3-6.	0.6	10
319	NKG2A and CD56 Are Coexpressed on Activated TH2 but Not TH1 Lymphocytes. Human Immunology, 2005, 66, 1223-1234.	2.4	10
320	Gene Selection for Multiclass Prediction by Weighted Fisher Criterion. Eurasip Journal on Bioinformatics and Systems Biology, 2007, 2007, 1-15.	1.4	10
321	Eps homology domain endosomal transport proteins differentially localize to the neuromuscular junction. Skeletal Muscle, 2012, 2, 19.	4.2	10
322	Global Gene Profiling of VCPâ€associated Inclusion Body Myopathy. Clinical and Translational Science, 2012, 5, 226-234.	3.1	10
323	Status of LEPR Gene in PCB-exposed Population: A Quick Look. International Journal of Human Genetics, 2013, 13, 27-32.	0.1	10
324	Homozygous mutation in Atlastin GTPase 1 causes recessive hereditary spastic paraplegia. Journal of Human Genetics, 2016, 61, 571-573.	2.3	10

#	Article	IF	Citations
325	A genetic variant in <scp>IL</scp>â€15RÎ± correlates with physical activity among Europeanâ€“American adults. Molecular Genetics & Genomic Medicine, 2018, 6, 401-408.	1.2	10
326	Orthogonal analysis of dystrophin protein and mRNA as a surrogate outcome for drug development. Biomarkers in Medicine, 2019, 13, 1209-1225.	1.4	10
327	Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice. PLoS ONE, 2021, 16, e0246507.	2.5	10
328	Additional dystrophin fragment in Becker muscular dystrophy may result from proteolytic cleavage at deletion junctions. American Journal of Medical Genetics Part A, 1992, 44, 378-381.	2.4	9
329	Translating Mighty Mice into Neuromuscular Therapeutics. American Journal of Pathology, 2006, 168, 1775-1778.	3.8	9
330	Effect of the SORT1 low-density lipoprotein cholesterol locus is sex-specific in a fit, Canadian young-adult population. Applied Physiology, Nutrition and Metabolism, 2013, 38, 188-193.	1.9	9
331	Salivary latent trait cortisol (LTC): Relation to lipids, blood pressure, and body composition in middle childhood. Psychoneuroendocrinology, 2016, 71, 110-118.	2.7	9
332	Neurodevelopmental Needs in Young Boys with Duchenne Muscular Dystrophy (DMD): Observations from the Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study (DNHS).. PLOS Currents, 2018, 10, .	1.4	9
333	Glucocorticoid Receptor (NR3C1) Variants Associate with the Muscle Strength and Size Response to Resistance Training. PLoS ONE, 2016, 11, e0148112.	2.5	9
334	A Dystrophin Exon-52 Deleted Miniature Pig Model of Duchenne Muscular Dystrophy and Evaluation of Exon Skipping. International Journal of Molecular Sciences, 2021, 22, 13065.	4.1	9
335	Mechanism of action and therapeutic route for a muscular dystrophy caused by a genetic defect in lipid metabolism. Nature Communications, 2022, 13, 1559.	12.8	9
336	Molecular diagnostics of Duchenne/Becker dystrophy: New additions to a rapidly expanding literature. Journal of the Neurological Sciences, 1991, 101, 129-132.	0.6	8
337	Development and production of an oligonucleotide MuscleChip: use for validation of ambiguous ESTs. BMC Bioinformatics, 2002, 3, 33.	2.6	8
338	Expression profiling and pharmacogenomics of muscle and muscle disease. Current Opinion in Pharmacology, 2003, 3, 309-316.	3.5	8
339	New molecular research technologies in the study of muscle disease. Current Opinion in Rheumatology, 2003, 15, 698-707.	4.3	8
340	Proteomic profiling of glucocorticoid-exposed myogenic cells: Time series assessment of protein translocation and transcription of inactive mRNAs. Proteome Science, 2009, 7, 26.	1.7	8
341	Knowledge-guided gene ranking by coordinative component analysis. BMC Bioinformatics, 2010, 11, 162.	2.6	8
342	Somatic mosaicism due to a reversion variant causing hemi-atrophy: a novel variant of dystrophinopathy. European Journal of Human Genetics, 2016, 24, 1511-1514.	2.8	8

#	Article	IF	Citations
343	Mechanisms of allelic and clinical heterogeneity of lamin A/C phenotypes. Physiological Genomics, 2018, 50, 694-704.	2.3	8
344	Genetic Variation in Acid Ceramidase Predicts Non-completion of an Exercise Intervention. Frontiers in Physiology, 2018, 9, 781.	2.8	8
345	Influence of Î²2 adrenergic receptor genotype on risk of nocturnal ventilation in patients with Duchenne muscular dystrophy. Respiratory Research, 2019, 20, 221.	3.6	8
346	Exposureâ€Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy. Journal of Clinical Pharmacology, 2020, 60, 1385-1396.	2.0	8
347	Dystrophin associated proteins fail in filling dystrophin's shoes. Nature Genetics, 1994, 8, 311-312.	21.4	7
348	Pyruvate Dehydrogenase Phosphatase Regulatory Gene Expression Correlates with Exercise Training Insulin Sensitivity Changes. Medicine and Science in Sports and Exercise, 2016, 48, 2387-2397.	0.4	7
349	The angiotensin-converting enzyme insertion/deletion polymorphism rs4340 associates with habitual physical activity among European American adults. Molecular Genetics & Genomic Medicine, 2017, 5, 524-530.	1.2	7
350	Expression of macrophage genes within skeletal muscle correlates inversely with adiposity and insulin resistance in humans. Applied Physiology, Nutrition and Metabolism, 2018, 43, 187-193.	1.9	7
351	Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies. Acta Myologica, 2020, 39, 179-186.	1.5	7
352	Evolution and comparative genomics of subcellular specializations: EST sequencing of Torpedo electric organ. Marine Genomics, 2011, 4, 33-40.	1.1	6
353	Understanding the molecular complexity of medulloblastoma. Nature Reviews Neurology, 2012, 8, 539-540.	10.1	6
354	A calm before the exome storm. Neurology, 2012, 78, 1706-1707.	1.1	6
355	Examination of Lifestyle Behaviors and Cardiometabolic Risk Factors in University Students Enrolled in Kinesiology Degree Programs. Journal of Strength and Conditioning Research, 2016, 30, 1137-1146.	2.1	6
356	Blunted circadian cortisol in children is associated with poor cardiovascular health and may reflect circadian misalignment. Psychoneuroendocrinology, 2021, 129, 105252.	2.7	6
357	Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy. Life, 2021, 11, 827.	2.4	6
358	Human molecular genetics and the elucidation of the primary biochemical defect in duchenne muscular dystrophy. Cytoskeleton, 1989, 14, 163-168.	4.4	5
359	Extensive genetic heterogeneity in the ?pure? form of autosomal dominant familial spastic paraplegia (Strï¿½mpell's disease). , 1996, 19, 1435-1438.		5
360	Biomarker Identification by Knowledge-Driven Multi-Level ICA and Motif Analysis. , 2007, , .		5

#	Article	IF	Citations
361	Strength, Size, and Muscle Quality in the Upper Arm following Unilateral Training in Younger and Older Males and Females. Clinical Medicine: Arthritis and Musculoskeletal Disorders, 2009, 2, CMAMD.S1180.	0.0	5
362	Characterization of the ZBTB42 gene in humans and mice. Human Genetics, 2011, 129, 433-441.	3.8	5
363	A rebirth for drisapersen in Duchenne muscular dystrophy?. Lancet Neurology, The, 2014, 13, 963-965.	10.2	5
364	Genetic characterization of physical activity behaviours in university students enrolled in kinesiology degree programs. Applied Physiology, Nutrition and Metabolism, 2017, 42, 278-284.	1.9	5
365	Discovery of potential urine-accessible metabolite biomarkers associated with muscle disease and corticosteroid response in the mdx mouse model for Duchenne. PLoS ONE, 2019, 14, e0219507.	2.5	5
366	Endothelial Nitric Oxide Synthase (NOS3) +894â€‰G>T Associates with Physical Activity and Muscle Performance among Young Adults. ISRN Vascular Medicine, 2012, 2012, 1-7.	0.7	4
367	Acute serum protein and cytokine response of single dose of prednisone in adult volunteers. Steroids, 2022, 178, 108953.	1.8	4
368	A mouse model of inherited choline kinase Î²-deficiency presents with specific cardiac abnormalities and a predisposition to arrhythmia. Journal of Biological Chemistry, 2022, 298, 101716.	3.4	4
369	Prenatal diagnosis in a family affected with Î²-sarcoglycan muscular dystrophy. Neuromuscular Disorders, 1999, 9, 323-325.	0.6	3
370	Computational analysis of muscular dystrophy sub-types using a novel integrative scheme. Neurocomputing, 2012, 92, 9-17.	5.9	3
371	Response to Comment on Sprouse et al.SLC30A8Nonsynonymous Variant Is Associated With Recovery Following Exercise and Skeletal Muscle Size and Strength. Diabetes 2014;63:363â€“368. Diabetes, 2014, 63, e9-e10.	0.6	3
372	Global Gene Expression Profiling in R155H Knock-In Murine Model of VCP Disease. Clinical and Translational Science, 2015, 8, 8-16.	3.1	3
373	Novel mutation identification and copy number variant detection via exome sequencing in congenital muscular dystrophy. Molecular Genetics & Genomic Medicine, 2020, 8, e1387.	1.2	3
374	The Influence of Metabolic Syndrome Risk Factors on Carotid Intima Media Thickness in Children. Global Pediatric Health, 2021, 8, 2333794X2098745.	0.7	3
375	Concerns Regarding Therapeutic Implications of Very Lowâ€Level Dystrophin. Annals of Neurology, 2021, 90, 176-176.	5.3	3
376	The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice. PLoS ONE, 2013, 8, e66617.	2.5	3
377	Influence of Î²2 adrenergic receptor genotype on longitudinal measures of forced vital capacity in patients with Duchenne muscular dystrophy. Neuromuscular Disorders, 2022, 32, 150-158.	0.6	3
378	Asthmatic Bronchial Epithelium Is Intrinsically Inflammogenic, Mitotically Dyssynchronous, And Is Rescued By Glucocorticoids. , 2010, , .		2

#	Article	IF	Citations
379	Dystrophinopathies. , 2015, , 1103-1111.		2
380	Transcriptional Cascades in Muscle Regeneration. , 2008, , 85-106.		2
381	Genome-Wide Association Studies in Muscle Physiology and Disease. , 2019, , 9-30.		2
382	PCB Exposure In Vitro (PBMC): Differential Gene Expression, Pathway Analysis for Possible Mode(s) of Actions, and Disease Development in Comparison with PCB-Exposed Slovak Population. Epidemiology, 2009, 20, S130.	2.7	2
383	Genetic modifiers of upper limb function in Duchenne muscular dystrophy. Journal of Neurology, 2022, 269, 4884-4894.	3.6	2
384	Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2021, 8, S369-S381.	2.6	1
385	Xâ€inactivation patterns in female Leber's hereditary optic neuropathy patients do not support a strong Xâ€linked determinant. American Journal of Medical Genetics Part A, 1996, 61, 356-362.	2.4	1
386	Novel Genetic Variation in Muscle Genes Correlated with Muscle Strength, Size and Response to Resistance Training (FAMuSS). Medicine and Science in Sports and Exercise, 2004, 36, S260.	0.4	1
387	Identification of Early Disease Biomarkers in 45 Months PCB-Exposed Slovak Population. Epidemiology, 2009, 20, S131.	2.7	1
388	GENE SELECTION BY WEIGHTED FISHER CRITERION FOR MULTICLASS PREDICTION. , 2005, , .		1
389	Genetic Modifiers of Cerebrovascular Large Vessel Stenosis in Sickle Cell Anemia.. Blood, 2004, 104, 1658-1658.	1.4	1
390	AKT1 Association with Body Composition. Medicine and Science in Sports and Exercise, 2007, 39, S14.	0.4	1
391	Decreased Platelet Expression of MYL9 (Myosin Regulatory Light Chain Polypeptide) and Other Genes with Platelets Dysfunction and CBFA2 Mutation: Insights from Platelet Expression Profiling.. Blood, 2004, 104, 737-737.	1.4	1
392	Platelet Granzyme B expression is increased in sepsis: a potential mechanism for sepsisâ€associated endothelial apoptosis. FASEB Journal, 2007, 21, A1125.	0.5	1
393	Response to Letter by Law. Cell Transplantation, 1993, 2, 438-438.	2.5	0
394	Molecular Diagnosis and Genetic Counseling of the Manifesting Carrier of Duchenne Muscular Dystrophy. , 2001, , 173-188.		0
395	Composite Gene Module Discovery using Non-negative Independent Component Analysis. , 2006, , .		0
396	Genetic medicine and the muscular dystrophies: triumphs and tribulations. Developmental Medicine and Child Neurology, 2002, 44, 136-140.	2.1	0

#	Article	IF	Citations
397	MHC Class II Deficiency. , 2009, , 1306-1308.		0
398	Computational Analysis of Muscular Dystrophy Sub-types Using a Novel Integrative Scheme. , 2010, , .		0
399	Predicting age at loss of ambulation in Duchenne muscular dystrophy with deep phenotypic measures. , 2014, , .		0
400	Biomarkers for Muscle Disease Gene Therapy. , 2019, , 239-252.		0
401	Asymmetric independence modeling identifies novel gene-environment interactions. Scientific Reports, 2019, 9, 2455.	3.3	0
402	Genetic medicine and the muscular dystrophies: triumphs and tribulations. Developmental Medicine and Child Neurology, 2002, 44, 136.	2.1	0
403	Microarray Analysis of Peripheral Blood Monocytes in Sickle Cell Anemia Patients with Cerebrovascular Stenosis.. Blood, 2004, 104, 3570-3570.	1.4	0
404	Skeletal muscle remodeling during hypertrophy involves the coordinated expression of growth and atrophy genes. FASEB Journal, 2006, 20, A392.	0.5	0
405	Elucidating the Role of SNPs in AKT1 Gene Expression. FASEB Journal, 2007, 21, A1152.	0.5	0
406	The Genomic Basis of Neuromuscular Disorders. , 2009, , 1265-1281.		0
407	Aging influences the expression of early response genes following acute resistance exercise in trained skeletal muscle. FASEB Journal, 2013, 27, 710.3.	0.5	0
408	Asymptomatic African Americans with highâ€risk APOL1 genotypes have reduced urinary angiogenesisâ€promoting cytokines. FASEB Journal, 2013, 27, lb474.	0.5	0
409	Molecular Diagnosis and Genetic Testing. , 2014, , 271-284.		0
410	ACTN3 genotype predicts metabolic, anthropometric and cardiovascular phenotypes in a young, healthy population (711.8). FASEB Journal, 2014, 28, 711.8.	0.5	0
411	Muscular Dystrophies. , 1998, , 859-863.		0
412	The SORT1 risk allele is associated with exaggerated postprandial lipaemia in young adults (383.5). FASEB Journal, 2014, 28, 383.5.	0.5	0
413	Muscular Dystrophies. , 2006, , 1080-1087.		0
414	Phenotypic-Specific Gene Module Discovery using a Diagnostic Tree and caBIGTM VISDA. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0

#	Article	IF	Citations
415	Latent Variable and nICA Modeling of Pathway Gene Module Composite. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0
416	Title is missing!. , 2020, 17, e1003222.		0
417	Title is missing!. , 2020, 17, e1003222.		0
418	Title is missing!. , 2020, 17, e1003222.		0
419	Title is missing!. , 2020, 17, e1003222.		0
420	Title is missing!. , 2020, 17, e1003222.		0
421	Title is missing!. , 2020, 17, e1003222.		0